BG BCMA
Alternative Names: Anti-BCMA CAR-T - Guangzhou Bio-gene Technology; BG-BCMALatest Information Update: 28 Jan 2024
At a glance
- Originator Guangzhou Bio-gene Technology
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Multiple myeloma
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for preclinical development in Multiple-myeloma in China (Parenteral)
- 09 Dec 2019 BG BCMA is available for licensing as of 05 Dec 2019. http://www.gzbiogene.com/english.php/
- 01 Dec 2019 Preclinical trials in Multiple myeloma in China (Parenteral) before December 2019 (Guangzhou Bio-gene Technology pipeline, December 2019)